Navigation Links
Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
Date:10/2/2008

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization.

In the previous phase II clinical trial, patients experienced substantially reduced reactions to cat allergens after a single administration of ToleroMune therapy. The current study builds on this work, and will explore different 4-dose treatment regimens, which are designed to enhance the patients' response and determine the best therapeutic approach. During the study, patients will receive a controlled dose of cat allergen in an environmental exposure chamber both before and after treatment, and will then complete a questionnaire to score their allergic rhinitis symptoms. This will allow investigators to evaluate the impact of the different treatment regimes. The double-blind, randomized, placebo-controlled trial will include a total of 120 volunteers with confirmed cat allergies. The study, which is already underway in Canada, is progressing well with approximately 20% of patients enrolled for screening so far.

"This study is of great importance for Circassia as it is designed to define the most effective treatment regime for our ToleroMune allergy products, and in particular for the phase III studies of our cat-allergy therapy that are planned to begin in the second half of 2009," said Steve Harris, Circassia's CEO. "The results of our trials to date show that our ToleroMune approach offers patients substantial potential benefits. Conventional allergy treatments either address symptoms only or require many doses over a period of months under specialist supervision because they can result in serious, even life-threatening adverse reactions. In contrast, Circassia's anti-allergy technology has the potential to provide effective but shorter treatments, while minimizing the threat of severe side-effects."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients.

Circassia's anti-allergy products offer potential important clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is also high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

For more information please visit http://www.circassia.co.uk.


'/>"/>
SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
3. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
4. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
10. Isis Initiates Clinical Trial of CRP Drug
11. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):